NASDAQ · Biotechnology · USD

Mustang Bio, Inc. Common Stock (MBIO) Stock Analysis

Mustang Bio, Inc. Common Stock (MBIO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

MBIO

$0.38

+$0.00 (+0.87%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MBIO with… →

MBIO Key Statistics

As of Oct 21, 2026

Trading

Open: $0.39
Previous Close: $0.38
Day's Range: 0.37–0.40
52-Week Range: 0.37–1.54
Volume: 28.57K
Beta: 2.09

Valuation

Market Cap: $2.90M
P/E Ratio: unprofitable
EPS (ttm): −0.44

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$1.92M
Shares Outstanding: 6.73M
1-Year Return: −75.30%

Dividend and dates

Avg Volume: 31.78K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, MBIO closed at $0.38, −75.30% over 1 year.

Mustang Bio, Inc. Common Stock (MBIO) has a market capitalization of $2.90M.

In fiscal 2025, MBIO reported revenue of $0.00.

MBIO Stock Return by Calendar Year

Mustang Bio, Inc. Common Stock (MBIO) return since Aug 2017: what $10,000 became

1 year: $10,000 $2,470; −75.30%
5 years: $10,000 $2; −99.98%
Since Aug 2017: $10,000 $0.52; −99.99%

If you had invested $10,000 in Mustang Bio, Inc. Common Stock (MBIO) at the close on August 22, 2017, the earliest close on record here, it would have been worth $0.52 at the close on October 21, 2026: −99.99% in total, −65.91% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+38.78%−88.92%−60.98%

2017*201820192020202120222023202420252026*

Year	Return
2026 (partial year)	−60.98%
2025	−88.92%
2024	−86.89%
2023	−77.22%
2022	−76.20%
2021	−56.14%
2020	−7.23%
2019	+38.78%
2018	−75.48%
2017 (partial year)	+22.35%

As of October 21, 2026.

MBIO Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$1.92M	—
2024	$0.00	−$15.75M	—
2023	$0.00	−$51.60M	—
2022	$0.00	−$77.53M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$2.43M	−$1.92M	—
2024	$0.00	—	−$12.55M	−$15.75M	—
2023	$0.00	—	−$50.73M	−$51.60M	—
2022	$0.00	—	−$76.16M	−$77.53M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Analysis

Data-derived

Company Overview

Mustang Bio, Inc. Common Stock (MBIO) carries a market capitalisation of $2.90M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 4 employees.

The most recent close on file for MBIO is $0.38, dated October 21, 2026. That is $0.00 (+0.87%) against the previous close. The 52-week range on file runs from $0.37 to $1.54. The latest close sits 3.46% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $1.92M. Earnings per share on a trailing basis come to −0.44.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The reported beta is 2.09. Annualized volatility over the trailing 9 years is 199.37%. The trailing one-year total return is −75.30%. Across 5 years the annualized return works out at −81.26%.

Growth & Income

The record shows no dividend for MBIO.

Across the complete calendar years on file, 2019 returned +38.78% and 2025 returned −88.92%. Of the 8 complete calendar years on file, 1 finished higher. 2026 is still running; the total return is −60.98% year to date.

Peer Comparison

Mustang Bio, Inc. Common Stock (MBIO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Mustang Bio, Inc. Common Stock	MBIO	$2.90M	—
Vertex Pharmaceuticals Incorporated	VRTX	$132.95B	30.4
Moderna, Inc.	MRNA	$98.14B	—
Regeneron Pharmaceuticals, Inc.	REGN	$82.95B	19.9

The Biotechnology industry average P/E ratio is 16.6x. Mustang Bio, Inc. Common Stock has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

MRNA

Moderna, Inc.

$98.14B

REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

ARGX

argenx SE

$55.97B

ONC

BeOne Medicines AG

$43.97B

RVMD

Revolution Medicines, Inc.

$41.64B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About Mustang Bio, Inc. Common Stock

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children's hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.

Visit website →